Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and the findings in terms of verbal severity score and tolerability.
The abstract ‘Real World Effectiveness and Tolerability of low-dose opiates for Refractory/Unexplained Chronic Cough (RCC/UCC) in a tertiary clinic.’ was presented at ERS 2022, 4–6 September, 2022.
Questions
- What is known about the effectiveness of low-dose opiates for refractory/unexplained chronic cough? (0:24)
- What were the aims and design of your real world study? (1:46)
- What were the study findings in terms of verbal severity score? (2:42)
- What were the tolerability findings? (4:31)
- What future studies are planned? (5:40)
Disclosures: James Wingfield Digby has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
